Dasatinib bms 2000 patent wo?

When does the Dasatinib BMS 2000 patent expire?

The patent protecting Dasatinib BMS 2000, also known as Sprycel, is set to expire in various regions over the coming years. In the United States, the primary patent for Dasatinib is scheduled to expire in 2027 [1]. However, it is important to note that patent landscapes can be complex, with multiple patents covering different aspects of a drug [2].

What other patents protect Dasatinib?

Beyond the main patent, there are additional patents associated with Dasatinib, including those related to specific formulations or methods of use. These secondary patents can sometimes extend market exclusivity beyond the expiry of the primary patent [2]. For detailed patent information on Dasatinib and its associated patents, DrugPatentWatch.com provides a comprehensive resource [1].

Why are companies interested in Dasatinib's patent status?

The expiration of patents for successful drugs like Dasatinib opens the door for generic competition. Pharmaceutical companies that manufacture generic versions of drugs typically wait for patent expiry or successful patent challenges to enter the market. This competition can lead to lower drug prices for patients and healthcare systems [3].

How does Dasatinib work?

Dasatinib is a tyrosine kinase inhibitor used to treat certain types of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1]. It works by blocking the action of specific enzymes that promote cancer cell growth [4].